Corcept Therapeutics Incorporated
Stock Forecast, Prediction & Price Target
Corcept Therapeutics Incorporated (CORT) stock Price Target by analysts
$78
Potential upside: 9.85%
Corcept Therapeutics Incorporated price prediction
What is Corcept Therapeutics Incorporated stock analysts` prediction?
Corcept Therapeutics Incorporated stock forecast: Based on 2 Wall Street analysts` predicted price targets for Corcept Therapeutics Incorporated in the last 3 months, the avarage price target is $78, with a high forecast of $NaN. The average price target represents a 9.85% change from the last price of $71.
Disclaimer: This is not investment advice. Don't use price targets as the only investment indicator. Always remember to do your own thorough research and due diligence before making an investment decision.
Corcept Therapeutics Incorporated stock Price Target by analysts
Full breakdown of analysts given Corcept Therapeutics Incorporated price targets
| Analyst name & company | Analyst win rate | Publish date | Price target | Price when posted | Source | Historical targets |
|---|---|---|---|---|---|---|
Swayampakula Ramakanth H.C. Wainwright | 0% 0/3 | 11 months ago | $80 12.67% upside | $47.17 | StreetInsider | Previous targets (2) |
Joon Lee Truist Financial | 0% 0/2 | 11 months ago | $76 7.04% upside | $43.93 | TheFly | Previous targets (1) |
Edward Nash Canaccord Genuity | 0% 0/2 | about 1 year ago | $78 9.85% upside | $34.71 | StreetInsider | Previous targets (1) |
Swayampakula Ramakanth H.C. Wainwright | 0% 0/3 | about 1 year ago | $45 -36.61% downside | $36.53 | StreetInsider | Previous targets (2) |
David Amsellem Piper Sandler | 0% 0/2 | about 1 year ago | $38 -46.47% downside | $36.12 | StreetInsider | Previous targets (1) |
Edward Nash Canaccord Genuity | 0% 0/2 | about 1 year ago | $38 -46.47% downside | $32.79 | StreetInsider | Previous targets (1) |
David Amsellem Piper Sandler | 0% 0/2 | about 1 year ago | $35 -50.70% downside | $31.51 | StreetInsider | Previous targets (1) |
Joon Lee Truist Financial | 0% 0/2 | over 1 year ago | $65 -8.45% downside | $31.59 | StreetInsider | Previous targets (1) |
Swayampakula Ramakanth H.C. Wainwright | 0% 0/3 | over 1 year ago | $40 -43.66% downside | $23.88 | StreetInsider | Previous targets (2) |
Unknown H.C. Wainwright | N/A | over 2 years ago | $30 -57.74% downside | $23.01 | Benzinga | N/A |
Unknown H.C. Wainwright | N/A | about 3 years ago | $33 -53.52% downside | $28.71 | Benzinga | N/A |
Corcept Therapeutics Incorporated Financial Estimates
Corcept Therapeutics Incorporated Revenue Estimates
Corcept Therapeutics Incorporated EBITDA Estimates
Corcept Therapeutics Incorporated Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $365.97M N/A | $401.85M 9.80% | $482.37M 20.03% | Avg: $715.61M Low: $647.35M High: $743.97M avg. 48.35% | Avg: $788.17M Low: $738.06M High: $834.68M avg. 10.14% | Avg: $899.94M Low: $842.72M High: $953.04M avg. 14.18% | Avg: $1.03B Low: $964.72M High: $1.09B avg. 14.47% |
Net Income
% change YoY
| $112.51M N/A | $101.41M -9.86% | $106.14M 4.65% | Avg: $155.10M Low: $61.45M High: $202.25M avg. 46.12% | Avg: $215.59M Low: $129.62M High: $241.36M avg. 39.00% | Avg: $263.71M Low: $241.91M High: $283.93M avg. 22.31% | Avg: $340.44M Low: $312.29M High: $366.55M avg. 29.09% |
EBITDA
% change YoY
| $124.47M N/A | $112.63M -9.51% | $108.32M -3.82% | Avg: $225.29M Low: $203.80M High: $234.22M avg. 107.98% | Avg: $248.13M Low: $232.36M High: $262.78M avg. 10.14% | Avg: $283.32M Low: $265.31M High: $300.04M avg. 14.18% | Avg: $324.34M Low: $303.71M High: $343.48M avg. 14.47% |
EPS
% change YoY
| $0.97 N/A | $0.95 -2.06% | $1.02 7.36% | Avg: $1.35 Low: $0.55 High: $1.81 avg. 32.54% | Avg: $1.78 Low: $1.16 High: $2.16 avg. 31.90% | Avg: $2.36 Low: $2.16 High: $2.54 avg. 32.33% | Avg: $3.05 Low: $2.79 High: $3.28 avg. 29.09% |
Operating Expenses
% change YoY
| $236.22M N/A | $283.83M 20.15% | $368.61M 29.86% | Avg: $246.42M Low: $222.91M High: $256.18M avg. -33.14% | Avg: $271.40M Low: $254.15M High: $287.42M avg. 10.14% | Avg: $309.89M Low: $290.19M High: $328.18M avg. 14.18% | Avg: $354.75M Low: $332.20M High: $375.69M avg. 14.47% |
FAQ
What is Corcept Therapeutics Incorporated stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 34.13% in 2025-2028.
We have gathered data from 5 analysts. Their low estimate is 61.45M, average is 155.10M and high is 202.25M.
What is Corcept Therapeutics Incorporated stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 21.78% in 2025-2028.
We have gathered data from 4 analysts. Their low revenue estimate is $647.35M, average is $715.61M and high is $743.97M.
What is Corcept Therapeutics Incorporated stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 31.47% in 2025-2028.
We have gathered data from 5 analysts. Their low earnings per share estimate is $0.55, average is $1.35 and high is $1.81.
What is the best performing analyst?
In the last twelve months 2 analysts have been covering Corcept Therapeutics Incorporated stock. The most successful analyst is Swayampakula Ramakanth.